Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZHAVG)

• Drug Name: VPM-4-001 Drug Info
• Synonyms: Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Preclinical	[1]

• Cross-matching ID: TTD Drug ID: DMZHAVG

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[3]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[4]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[5]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[6]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[7]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[9]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[10]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[11]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[12]

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[13]
Fumaric acid	DMP83UZ	Multiple sclerosis	8A40	Phase 3	[14]
VIR-201	DMAMIU4	Human immunodeficiency virus infection	1C62	Phase 1/2	[15]
CIGB-128	DMB2MKU	Basal cell carcinoma	2C32	Phase 1	[16]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[17]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[18]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[19]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[20]
TG-1042	DMS4BUK	B-cell lymphoma	2A86	Discontinued in Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Not Available	[2]
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Not Available	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023655)
• [2] BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [6] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [7] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [8] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [9] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [10] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [11] Clinical pipeline report, company report or official report of Immunservice.
• [12] National Cancer Institute Drug Dictionary (drug id 665656).
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
• [15] EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
• [16] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [17] Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
• [18] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [19] T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
• [20] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [21] Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.